BriaCell Therapeutics EBIT

BriaCell Therapeutics (BCT.TO) currently reports a EBIT of $-31M as of July 2026. That compares with $-26M in the prior-year period — down 15.4% year over year. That is below the Healthcare sector average of $99B. Use the charts on this page to explore BriaCell Therapeutics's EBIT history and peer comparisons.

BriaCell Therapeutics's EBIT decreased from $-26M to $-31M — a 15.4% year-over-year decrease (period ending July 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BriaCell Therapeutics's EBIT of $-31M is lower than the Healthcare sector average of $99B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

BriaCell Therapeutics reported $-31M in EBIT as of July 2026. That compares with $-26M in the prior-year period — down 15.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-31M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for BriaCell Therapeutics, and consider following BCT.TO for alerts when major investors trade the stock.